[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587427":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":79,"collaborators":83,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":96,"maxAge":24,"enrollmentInfo":97,"targetDuration":24,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":67,"whyStopped":24,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Onabotulinum Toxin Type A - Phase 1b","EXPERIMENTAL","Onabotulinum toxin administered to two lesions.",[13],"Drug: Onabotulinum Toxin Type A - Phase 1b",{"label":15,"type":10,"description":16,"interventionNames":17},"Onabotulinum Toxin Type A - Phase 2","Onabotulinum toxin administered to three lesions.",[18],"Drug: Onabotulinum Toxin Type A - Phase 2",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.",[15],[29],{"name":30,"affiliation":5,"role":31},"Daniel Kaplan, MD, PhD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"Charity Ruhl, LPN","CONTACT","4126472013","ruhlcl@upmc.edu",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Anna Davis, MD","4126475633","davisa60@upmc.edu",[43,65],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University of Pittsburgh Medical Center","NOT_YET_RECRUITING","Pittsburgh","Pennsylvania","15213","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-79.99589,40.44062,{"lat":55,"lon":54},[58,59,60,62],{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},{"name":61,"role":31,"phone":24,"phoneExt":24,"email":24},"Daniel H Kaplan, MD, PhD",{"name":63,"role":64,"phone":24,"phoneExt":24,"email":24},"Joe K Tung, MD, MBA","SUB_INVESTIGATOR",{"facility":66,"status":67,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"UPMC Department of Dermatology","RECRUITING",{"type":52,"coordinates":69},[54,55],{"lat":55,"lon":54},[72,76,77],{"name":73,"role":35,"phone":74,"phoneExt":24,"email":75},"Neethi Francis, MA","4126474023","francisn2@upmc.edu",{"name":34,"role":35,"phone":40,"phoneExt":24,"email":37},{"name":78,"role":64,"phone":24,"phoneExt":24,"email":24},"Joe Tung, MD, MBA",{"type":80,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Daniel Kaplan","Professor",[84],{"name":85,"class":86},"Almirall, S.A.","INDUSTRY","100587427","phase-1-the-impact-of-botox-on-neuroimmune-interactions-in-atopic-dermatitis-100587427",false,"NCT06928246","The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis","Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis","AD","Inclusion Criteria:\n\nPhase 1b:\n\n* Patients 18 years or older at time of consent\n* Mild-to-Moderate AD, defined as:\n* BSA ≤ 10%\n* IGA ≤ 3\n* No past biologic therapy\n* No systemic therapy for 3 months\n* No topical therapy for treatment of AD for 4 weeks\n\nPhase 2:\n\n* Patients 18 years or older at time of consent\n* Mild-to-Moderate AD, defined as:\n* BSA ≤ 10%\n* IGA ≤ 3\n* At least one patch of eczema of at least 5 cm in diameter\n* No past biologic therapy\n* No systemic therapy for 3 months\n* No topical therapy for treatment of AD for 4 weeks\n\nExclusion Criteria:\n\nPhase 1b:\n\n* Age less than 18 years old\n* Pregnant or breastfeeding\n* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure\n* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks\n* Has used topical therapy for treatment of AD within 4 weeks\n\nPhase 2:\n\n* Patients enrolled in Phase 1\n* Age less than 18 years old\n* Pregnant or breastfeeding\n* Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure\n* Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks\n* Has used topical therapy for treatment of AD within 4 weeks","ALL","18 Years",{"count":98,"type":99},8,"ESTIMATED","INTERVENTIONAL",[102],"PHASE1","The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.",[105],"Atopic Dermatitis (AD)",[107,108,109],"Atopic dermatitis","Eczema","Botox","2026-05-01",{"date":112,"type":113},"2026-05-04","ACTUAL",{"date":115,"type":113},"2025-07-17",{"date":117,"type":99},"2027-01",{"name":81,"class":6},2]